Low-birth-weight infants are more likely to survive if born in hospitals having high performing Neonatal Intensive Care Units, revealed by researchers in a recent study.
A colon cancer researcher at the Ireland Cancer Center of University Hospitals Case Medical Center (UHCMC) has laid out the roadmap for how medical science should employ aspirin and new aspirin-like drugs for use in preventing colon cancer in certain high-risk individuals.
The following is a Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, ‘Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes’:
Some cancers seem to be linked to extremely low frequency electromagnetic fields, suggests research published ahead of print in Occupational and Environmental Medicine.
The scenario unfolds almost every day in the United States. A crowd gathers at a playground, or perhaps on a soccer field. A child has fallen to the ground, gripped by a seizure.
GlaxoSmithKline announced an important milestone for advanced breast cancer patients across Europe with approval of the first oral ErbB1 and ErbB2 dual inhibitor, Tyverb? (lapatinib).
A James P. Wilmot Cancer Center scientist recently received two research grants, totaling more than $1.5 million, for separate, divergent studies of new therapies for follicular and mantle cell lymphomas.
Injecting botulinum toxin A, or Botox, into the prostate gland of men with enlarged prostate, eased symptoms and improved quality of life up to a year after the procedure, according to a study by researchers at the Chang Gung University Medical College, Taiwan, and the University of Pittsburgh School of Medicine.
Aspirin therapy?s ability to reduce the risk of colorectal cancer, an association seen in a large number of studies, appears to depend on the drug?s inhibition of the COX-2 enzyme, the action that also underlies aspirin?s usefulness for treating pain and inflammation.
Statement from the American Association of Clinical Endocrinologists regarding The New England Journal of Medicine article, ?Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes.?